Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18006694 | 0.84 | TRPV4 (0.50) | TRPV4LOXL2TAAR1MAOB | |
| SCHEMBL12763652 | 0.77 | TRPV4 (0.52) | TRPV4EGLN2 | |
| SCHEMBL6705973 | 0.77 | TRPV4 (0.52) | TRPV4EGLN2 | |
| SCHEMBL2801373 | 0.77 | TRPV4 (0.52) | TRPV4PDCD1CD274EGLN2 | |
| SCHEMBL27957790 | 0.77 | LOXL2 (0.36) | LOXL2TAAR1 | |
| SCHEMBL24837935 | 0.77 | LOXL2 (0.36) | LOXL2TAAR1 | |
| SCHEMBL17316422 | 0.77 | TRPV4 (0.52) | TRPV4EGLN2 | |
| SCHEMBL15955535 | 0.74 | TRPV4 (0.48) | TRPV4EGLN2 | |
| SCHEMBL2726074 | 0.74 | TRPV4 (0.48) | TRPV4EGLN2 | |
| SCHEMBL18130434 | 0.74 | TRPV4 (0.48) | TRPV4LOXL2EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051460-A | Plasma kallikrein inhibitors | 瑞泽路特有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-101264051-B | Modified release pharmaceutical formulation | ASTRAZENECA AB | 2010-12-22 | — | — | CN | disclosed |
| US-7803954-B2 | Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| US-7781424-B2 | a time-release composition comprising antithrombins such as (2S)-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide, hydroxy propyl methyl cellulose and sodium stearyl fumarate as a lubricant; cardiovascular disorder | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-7763597-B2 | Salts | ASTRAZENECA AB (SE) | 2010-07-27 | — | — | US | disclosed |
| CN-101735131-A | New salts | ASTRAZENECA AB | 2010-06-16 | — | — | CN | disclosed |
| EP-2186800-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | Astra Zeneca AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| US-7700582-B2 | Pharmaceutical formulation | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | INGHARDT TORD | 2010-04-08 | — | — | US | disclosed |
| EP-1347955-B1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| EP-1401502-A1 | PHARMACEUTICAL FORMULATION | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101423-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101424-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101957-A1 | NEW SALTS | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003018551-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003000293-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | TRPV4 3575/4885LOXL2 3176/4885NSD2 3943/4885 |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | TFPI, F2R, F2 | TRPV4 4080/4885LOXL2 3594/4885NSD2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.